These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The cost of psoriasis treatment. Galadari I; Rigel E; Lebwohl M J Eur Acad Dermatol Venereol; 2001 Jul; 15(4):290-1. PubMed ID: 11730031 [No Abstract] [Full Text] [Related]
9. Cost analysis of psoriasis treatments. Giaquinta D Manag Care Interface; 2006 Jun; 19(6):37-8. PubMed ID: 16892659 [No Abstract] [Full Text] [Related]
10. Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis. Simpson JF; Yelverton CB; Balkrishnan R; Fleischer A; Lide W; Feldman SR Manag Care Interface; 2006 Jun; 19(6):39-43. PubMed ID: 16892660 [TBL] [Abstract][Full Text] [Related]
11. [How much should a psoriatic spot cost?]. Gjersvik PJ Tidsskr Nor Laegeforen; 2004 Jan; 124(1):14. PubMed ID: 14716384 [No Abstract] [Full Text] [Related]
12. Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany. Augustin M; Radtke M; van Engen A; Ruedig C; Lapp C; Moehling U J Dtsch Dermatol Ges; 2009 Apr; 7(4):329-38. PubMed ID: 19243481 [TBL] [Abstract][Full Text] [Related]
13. Consensus guidelines for specialty pharmaceuticals: a best-practice approach for cost-effective management. Sullivan SD Am J Manag Care; 2004 Aug; 10(8 Suppl):S242-4; discussion 245-51. PubMed ID: 15460521 [No Abstract] [Full Text] [Related]
14. Cost-effectiveness model of topical treatment of mild to moderate psoriasis vulgaris in Germany. A comparison of calcipotriol/betamethasone (Daivobet/Dovobet/Taclonex) once daily and a morning/evening non-fix combination of calcipotriol and betamethasone. Augustin M; Peeters P; Radtke M; Moehling U; Lapp C Dermatology; 2007; 215(3):219-28. PubMed ID: 17823519 [TBL] [Abstract][Full Text] [Related]
15. Incremental cost-effectiveness ratio analysis of biologic treatments for psoriasis at clinically significant evaluation time points. Puig L; López-Ferrer A; Vilarrasa E Actas Dermosifiliogr; 2014 Dec; 105(10):951-3. PubMed ID: 24836110 [No Abstract] [Full Text] [Related]
16. Back to the future: the managed care approach to rheumatoid arthritis. Sidorov J Manag Care Interface; 2007 Jul; 20(7):28-30. PubMed ID: 17849731 [TBL] [Abstract][Full Text] [Related]
17. The impact of psoriasis on health care costs and patient work loss. Fowler JF; Duh MS; Rovba L; Buteau S; Pinheiro L; Lobo F; Sung J; Doyle JJ; Swensen A; Mallett DA; Kosicki G J Am Acad Dermatol; 2008 Nov; 59(5):772-80. PubMed ID: 19119095 [TBL] [Abstract][Full Text] [Related]
18. Chronic insomnia treatment and Medicare Part D: implications for managed care organizations. Navarro R; Mitrzyk BM; Bramley TJ Am J Manag Care; 2007 Nov; 13(5 Suppl):S121-4. PubMed ID: 18041872 [TBL] [Abstract][Full Text] [Related]
19. Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States. Jhaveri M; Seal B; Pollack M; Wertz D Curr Med Res Opin; 2007 Jun; 23(6):1431-43. PubMed ID: 17559740 [TBL] [Abstract][Full Text] [Related]
20. The annual cost of psoriasis. Arikian SR; Einarson TR J Am Acad Dermatol; 1994 Jun; 30(6):1047-8. PubMed ID: 8188881 [No Abstract] [Full Text] [Related] [Next] [New Search]